Diabetes Drug Study Shows Promise of Personalized Medicine
Research by Mitchell Lazar, MD, PhD, director of the Institute for Diabetes, Obesity, and Metabolism, and Raymond Soccio, MD, PhD, clinical fellow in Endocrinology, Diabetes, and Metabolism, was featured in news outlets this week, including the Philadelphia Inquirer. In the first study of its kind, they have shown how an anti-diabetic drug can have variable effects depending on small natural differences in DNA sequence between individuals. They aim to apply this knowledge to develop personalized approaches to treating diabetes and other metabolic disorders.
The study explains how Rev-erbα regulates the clock in most cells of the body while also regulating metabolic genes in the liver. Instead of relying on the same mechanism for both these functions, Rev-erbα performs each of these jobs in distinct ways. This research may provide a new map for scientists wanting to treat metabolic syndrome.
>> Medical Daily article